Trial · NCT01824264
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks | baseline, 12 weeks | Change from baseline in HbA1c after 12 weeks of treatment in each of the LIK066 doses and placebo |
| Secondary | Change from baseline in Fasting Plasma Glucose | baseline, 12 weeks | The effect of LIK066 on fasting plasma glucose after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in urinary glucose to creatinine ratio | baseline, 12 weeks | The effect of LIK066 on urinary glucose to creatinine ratio after 12 weeks of treatment will be evaluated |
| Secondary | Change from baseline in Body weight | baseline, 12 weeks | The effect of LIK066 on change in body weight after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in Blood pressure | baseline, 12 weeks | The effect of LIK066 on change in systolic and diastolic blood pressure after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in postprandial glucose during a meal test | baseline, 12 weeks | The effect of LIK066 on change in postprandial glucose during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in beta cell function during a meal test | baseline, 12 weeks | The effect of LIK066 on change in beta cell function during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in insulin secretion relative to glucose during a meal test | baseline, 12 weeks | The effect of LIK066on change in insulin secretion relative to glucose during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in oral glucose insulin sensitivity during a meal test | baseline, 12 weeks | The effect of LIK066 on change in oral glucose insulin sensitivity during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in glucagon-like peptide response during a meal test | baseline, 12 weeks | The effect of LIK066 on change in glucagon-like peptide during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Change from baseline in Peptide YY response during a meal test | baseline, 12 weeks | The effect of LIK066 on change in peptide YY response during a meal test after 12 weeks of treatment will be evaluated. |
| Secondary | Number of patients with adverse events to assess safety and tolerability of LIK066 | 12 weeks | The safety and tolerability of 7 doses of LIK066 after 12 weeks of treatment will be evaluated with number of patients reported for total adverse events, serious adverse events and death. |
| Secondary | Change from baseline in renal threshold for glucose excretion | baseline, 12 weeks | The effect of LIK066 on renal threshold for glucose excretion will be calculated from glucose values in an overnight urine collection |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01824264/registered